Simulation of Conditions and Results of Implementation of Short-Course Treatment Regimes in Tuberculosis Patients

Author:

Burykhin V. S.1,Vasilyeva I. A.1ORCID,Sterlikov S. A.1,Testov V. V.1,Kudrina V. G.2,Urushadze N. D.1

Affiliation:

1. National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of Health

2. Russian Medical Academy of On-going Professional Education, Russian Ministry of Health

Abstract

The objective: to study the conditions of implementation of short-course (4 and 9 months) treatment regimens in tuberculosis patients and simulate their impact on the frequency of early treatment interruption (ETI) by patients.Subjects and Methods. Data on the treatment duration from enrollment to chemotherapy interruption in 8,029 tuberculosis patients were studied. Data were obtained from the Federal Register of Tuberculosis Cases for 2020. Of these, 3,379 patients were treated with regimens for susceptible or suspected susceptible tuberculous mycobacteria excluding isoniazid resistant tuberculosis, and 4,650 patients received regimens for rifampicin-resistant tuberculous mycobacteria.Results. The median duration of treatment from onset to ETI was 124 (95% CI 120-128) days in 3,379 patients, 224 (95% CI 215-233) days in 4,650 patients, or 170 (95% CI 157-181) days if there was a history of treatment interruption. Simulation of ETI terms when short-course chemotherapy regimens were introduced has shown that we can expect a 2-fold decrease in the proportion of patients who interrupted chemotherapy among patients with preserved/suspected susceptibility of tuberculous mycobacteria, and 1.3-1.7-fold decrease among patients with confirmed/presumed drug resistance of tuberculous mycobacteria at least to rifampicin.

Publisher

LLC "Medical Knowledge and Technologies"

Subject

General Medicine

Reference11 articles.

1. Baryery v dostupe k lecheniyu tuberkuleza glazami patsiyentov, zhivushchikh s VICH-infektsiyey i tuberkulezom v Rossii. [Barriers to accessing treatment of tuberculosis from the point of view of HIV-infected patients in Russia]. Available: https://evanetwork.ru/wp-content/uploads/2015/06/Bareryi-v-dostupe-k-lecheniyu-tu berkul eza-glazami-patsientov-zhivushhih-s-VICH_1.pdf. Accessed: 18.07.2023 г.

2. Vasilyeva I.A., Sterlikov S.A., Testov V.V., Mikhaylova Yu.V., Obukhova O.V., Ponomarev S.B., Kudlay D.A. Otraslevye i ekonomicheskiye pokazateli protivotuberkulyoznoy raboty v 2019-2020 gg. Statisticheskiye materialy. [Sectoral and economic rates of tuberculosis control in 2019-2020. Statistic materials]. Moscow, FGBU NMITS FPI Minzdrava Rossii Publ., 2022, 64 p.

3. Maryandyshev A.O., Kulizhskaya A.I., Khimova E.S., Perkhin D.V., Sveshnikova O.M., Presnova S.E., Kurochkina N.P., Sotnikov A.S., Lesheva N.A., Vasilyeva I.A. Short course treatment regimens for multiple drug resistant tuberculosis in Arkhangelsk, Murmansk and Belgorod Regions. Tuberculosis and Lung Diseases, 2019, vol. 97, no. 7, pp. 5-10. (In Russ.) https://doi.org/10.21292/2075-1230-2019-97-7-5-10.

4. Ungureanu T.N., Grzhibovskiy A.M. Comparison of three or more independent groups using the nonparametric Kraskell-Wallis criterion in the STATA program. Ekologiya Cheloveka, 2014, no. 6, pp. 55-58. (In Russ.)

5. Shurygin A.A., Makarova E.A. The effect of early treatment interruption on treatment efficacy. Mediko-Farmatsevticheskiy Journal Puls, 2021, vol. 23, no. 9, pp. 136-141. (In Russ.)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3